AURLUMYN Drug Patent Profile
✉ Email this page to a colleague
When do Aurlumyn patents expire, and when can generic versions of Aurlumyn launch?
Aurlumyn is a drug marketed by Eicos Sci and is included in one NDA.
The generic ingredient in AURLUMYN is iloprost. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iloprost profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AURLUMYN?
- What are the global sales for AURLUMYN?
- What is Average Wholesale Price for AURLUMYN?
Summary for AURLUMYN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 5,446 |
| What excipients (inactive ingredients) are in AURLUMYN? | AURLUMYN excipients list |
| DailyMed Link: | AURLUMYN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AURLUMYN
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for AURLUMYN
| Drug Class | Prostacycline |
US Patents and Regulatory Information for AURLUMYN
AURLUMYN is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AURLUMYN is ⤷ Sign Up.
This potential generic entry date is based on TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting AURLUMYN
TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS
Exclusivity Expiration: ⤷ Sign Up
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eicos Sci | AURLUMYN | iloprost | SOLUTION;INTRAVENOUS | 217933-001 | Feb 13, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eicos Sci | AURLUMYN | iloprost | SOLUTION;INTRAVENOUS | 217933-001 | Feb 13, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for AURLUMYN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | Ventavis | iloprost | EMEA/H/C/000474 Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms. |
Authorised | no | no | no | 2003-09-15 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
